Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announced today that 70-90% of primary care physicians recently surveyed anticipate that their overall use of hormone replacement therapy (HRT) will decrease as a result of the conclusions reached by the Women's Health Initiative (WHI) and Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II) trials. In sharp contrast to the primary care physicians surveyed in the latest PhysicianForum report, The Impact of the WHI and HERS II Trial Results on Hormone Replacement Therapy Management, thought- leading obstetrician/gynecologists indicate that they will make only moderate changes in their overall HRT management of patients.

(Photo: )

"Our study indicates that since the unexpected findings of the WHI and HERS II trials were released, many primary care physicians will be quick to change HRT management of their patients," said Alice von Loesecke, senior director of research for PhysicianForum. "Primary care physicians surveyed said that they would modify their use of HRT based on the patient's uterine status. The change in management will be highest for patients with an intact uterus, as 67% of primary care physicians said they will significantly decrease the use of HRT in this patient population. Some of these patients will have their HRT discontinued immediately; others will remain on HRT until their duration of therapy reaches the time limit their physician considers to be safe."

The Impact of the WHI and HERS II Trial Results on Hormone Replacement Therapy Management concludes that although PCPs are significantly changing the way they manage HRT, thought-leading obstetrician/gynecologists plan moderate changes to the management of HRT. This group of specialists will continue to support a viable, though smaller, HRT market.

"All of the thought-leading specialists interviewed for this report state that they discuss the risks and benefits of HRT management with their patients, and that the WHI/HERS II results do not significantly change their view of the risk/benefit profile for HRT," said Ms. von Loesecke. "Twenty percent will decrease their overall use of HRT in patients without an intact uterus, and 80% foresee their use declining in patients with an intact uterus."

The Impact of the WHI and HERS II Trial Results on Hormone Replacement Therapy Management includes surveys of 66 U.S.-based physicians (primary care physicians with large practices as well as thought-leading specialists). The surveys were conducted between July 18, 2002, and July 24, 2002.

HRT Recent Controversy

The long-term effects of HRT have been debated in the medical profession for the past several decades. The recent results from the WHI and the Study HERS II trials have added to the controversy because they demonstrate increased risk of stroke events, coronary heart disease events, or contracting invasive breast cancer with long-term use of Prempro.

About PhysicianForum

PhysicianForum is a new primary research service from Decision Resources. The service offers access to high-volume-prescribing primary care physicians, specialists, and managed care representatives in the United States and Europe; analysis of events and responses to them; insight into prescribing patterns; and predictions for the pharmaceutical market based on the results.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

All company brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:    Elizabeth Marshall    Decision Resources    781-296-2563 


Photo: NewsCom:

AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563, or

Pfizer's Blockbuster Viagra Faces Competition from New Oral Therapies from Eli Lilly and Bayer

View Now